AMRI Stock Tumbles After Announcing B-MS Trial Ends

By Zachary Brennan

- Last updated on GMT

AMRI Stock Tumbles After Announcing B-MS Trial Ends

Related tags Food and drug administration Bristol-myers squibb Amri

Albany Molecular Research's (AMRI) stock fell more than 10% on Monday after announcing in an SEC filing that it was informed by its partner Bristol-Myers Squibb that it would terminate the development of an investigational depression drug.

But the decision to cease the drug’s development, which was in Phase II of clinical development, is expected to “have no impact on AMRI’s financial guidance or forecasts, including, the company’s financial guidance for the third quarter and full year 2013​,” AMRI said.

The partnership between AMRI and BMS began in 2005 and has been a source of revenue for AMRI in the past due to payments for research and milestones reached on some compounds.

The drug in question was a triple reuptake inhibitor in development for treatment-resistant depression.

The announcement of the trial’s end comes as the company recently received a Form 483 at its Burlington, Massachusetts, plant​ after the US FDA re-inspected it.  

Despite these setbacks, AMRI CEO Thomas D’Ambra said last week in an earnings call​ that the company still expects to be profitable by the end of the year.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars